Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vanda Pharmaceuticals

4.77
-0.1500-3.05%
Post-market: 4.830.0601+1.26%19:52 EDT
Volume:606.83K
Turnover:2.92M
Market Cap:278.17M
PE:-14.45
High:4.96
Open:4.95
Low:4.75
Close:4.92
Loading ...

Vanda Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
05 Nov 2024

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

Benzinga
·
02 Nov 2024

HC Wainwright Starts Vanda Pharmaceuticals With Buy Rating, $18 Price Target

MT Newswires Live
·
01 Nov 2024

Street Seen Sleeping on Sleep-Drug Maker Vanda -- Market Talk

Dow Jones
·
31 Oct 2024

Vanda Pharmaceuticals Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
31 Oct 2024

Vanda Pharmaceuticals Inc : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $18

THOMSON REUTERS
·
31 Oct 2024

Vanda Pharmaceuticals: Strong Buy Rating Backed by Diversified Portfolio and Robust Pipeline

TIPRANKS
·
31 Oct 2024

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

PR Newswire
·
31 Oct 2024

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

Zacks
·
18 Oct 2024

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises

Zacks
·
15 Oct 2024

Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group

Dow Jones
·
15 Oct 2024

BUZZ-U.S. STOCKS ON THE MOVE-Adobe, BigBear.ai, PG&E

Reuters
·
15 Oct 2024

Vanda Pharmaceuticals Rejects Cycle Pharma's Second Takeover Offer, Shares Last up 10.8%

THOMSON REUTERS
·
14 Oct 2024

Vanda Pharmaceuticals Shares Rise; Cycle Pharmaceuticals' Buyout Offer Rejected Again

MT Newswires Live
·
14 Oct 2024

Vanda Pharmaceuticals: Cycle offer ‘substantially undervalues’ Vanda

TIPRANKS
·
14 Oct 2024

BRIEF-Vanda Pharmaceuticals Rejects Cycle Group's Second Non-Binding Proposal

Reuters
·
14 Oct 2024